TERN-701, an oral BCR-ABL inhibitor for chronic myeloid leukemia, completes dose escalation phase with promising safety profile and molecular responses in heavily pre-treated patients.
Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.
Terns Pharmaceuticals announced positive Phase I data for TERN-701, an allosteric BCR-ABL inhibitor, in relapsed/refractory chronic myeloid leukemia (CML).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.